Roche closes Igen deal
This article was originally published in The Gray Sheet
Executive Summary
BioVeris stock commences trading on the Nasdaq exchange Feb. 17 under the symbol "BIOV," following completion of Roche Diagnostic's $1.4 bil. acquisition of Igen International (1"The Gray Sheet" July 28, 2003, p. 5). BioVeris, spun-off from Igen, is based in Gaithersburg, Md. and will be led by former Igen management. The firm will assume the ongoing biodefense, lifescience and clinical diagnostic Igen businesses. Former Igen shareholders received $47.25 in cash from Roche and one share of BioVeris for each Igen share held...
You may also be interested in...
Meso Scale Diagnostics CEO Prompts BioVeris Nasdaq Delistment
BioVeris will file a request by August for a Nasdaq Listing Qualifications Panel to review a staff determination and stay the firm's stock delistment
Roche Purchase of Igen Resolves Licensing Dispute, Preserves Technology
Roche Diagnostics will retain roughly $400 mil. in annual revenues through the $1.4 bil. acquisition of Origen electrochemilumunescence technology licensor Igen International
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.